Redefining Surrogate Endpoints for Enhanced Efficacy in Novel Immunotherapies
Time: 2:40 pm
day: Day 1 Track B PM
Details:
- Building cell-free DNA (cfDNA) for tumor informed and tumor naive panel to monitor tumor mutational burden (TMB)
- Identifying biochemical molecular responses and translating them using biopsy sequencing and ex vivo immunology assays
- Identifying mechanisms of action to drive individual translational assays built for personalized medicine
